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 Myocardial infarction (MI), commonly known as a heart attack, is the irreparable 
necrosis of the cardiac tissue due to sustained ischemia. MI may lead to heart failure. Despite 
advances in treatments, the number of patients with heart failure is increasing. Engineered heart 
tissue, EHT, could offer an innovative approach to treating areas of infarcted cardiac tissue. 
Ideally, EHT should integrate and function with the native heart without causing a higher risk for 
complications. The purpose of this study is to design a system to identify potentially 
arrhythmogenic sites in EHT.  Specifically, an electrode array complete with DAQ system and 
data analysis program was developed to record electrical propagation and interpret conduction 
velocity (CV) speeds to identify areas of slow conduction. This system has the ability to analyze 
the activation times, calculate CV vector fields, and identify areas within the mapping window 
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I. Introduction 
A. Myocardial Infarction  
Myocardial infarction (MI), or more commonly known as a heart attack, is the irreparable 
necrosis of the cardiac tissue due to sustained ischemia. This lack of blood flow to an area of the 
heart can arise from many different sources such as coronary heart disease (CHD) and/or blood 
clots that block an artery to the heart [1]. MI is a life threatening condition that if not treated 
correctly could lead to heart failure. Approximately 1.5 million cases of MI occur annually in the 
US alone. The Global Burden of Disease study found that in 2010 an estimated 29.6% of deaths 
worldwide were caused by cardiovascular disease. In 2011, an MI was one of the top five most 
expensive inpatient hospitalizations in the US [2]. Currently, ischemic heart disease is the 
leading cause of death worldwide. According to the American Heart Association, about every 43 
seconds, someone in the United States has a myocardial infarction [3].   
An MI may lead to heart failure, arrhythmia, or cardiac arrest. Risk factors include, but 
are not limited to, diabetes, smoking, lack of exercise, obesity, high blood pressure, and high 
blood cholesterol. The most common symptoms of MI include chest discomfort, upper body pain 
that may spread beyond the chest to the arms, shoulders, back and neck, stomach pain that may 
mimic heartburn, shortness of breath, anxiety, dizziness, sweating, nausea and vomiting. Most 
heart attacks typically begin as discomfort rather than immediate pain and begin to increase in 
severity over the course of several minutes [6]. In 2005, 92% of respondents recognized chest 






B. Post Myocardial Infarction Interventions 
Identification and treatment after MI is critical for a successful recovery of the patient. 
Immediate intervention for this circumstance may include aspirin, diuretic, beta-blockers, other 
antiarrhythmic drugs, as well as the use of and electrical defibrillator for cases of severe 
arrhythmic episodes [1]. Depending on the extent of tissue damage, surgical procedures, such as 
RF ablation, or the use of an implantable device, such as a defibrillator or pacemaker, may be 
used [8].  
Certain medications, in particular anticoagulants, are able to prevent blood clotting. This 
decreases both formation of new blood clots and continued growth of existing clots. These drugs 
have the ability to stop or decrease growth rate of existing blood clots, not break them down. The 
purpose of this particular treatment is to prevent the blood clots from moving into a location that 
would prevent oxygen to an area of the cardiac tissue. In order to decrease potential fluid 
accumulation, diuretic drugs are administered. Diuretics enable the body to reduce excess fluids 
and sodium through urination. This helps reduce blood pressure and reduce the heart’s workload. 
This also prevents build up of fluids in the lungs and other parts of the body [9]. Beta-blockers, 
or beta-adrenergic blocking agents, are medications that help reduce blood pressure by inhibiting 
the effects of epinephrine. When beta-blockers are administered, the heart beats slower and with 
less force, thereby reducing blood pressure, chest pain, and the chance of mild arrhythmias. They 
are also able to help blood vessels relax which improves blood flow [10].  
Depending upon the severity of the MI, angioplasty may be necessary. Angioplasty, also 
know as percutaneous coronary intervention, is used to physically widen a blood vessel where 
blood flow is restricted or blocked. This is accomplished by inserting a catheter with a 
uninflated balloon typically through the femoral or radial artery to gain access to the vascular 
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system. Once placed at the affected site, the balloon is expanded to enlarge the vessel and 
restore proper blood flow. Often times angioplasty is combined with the permanent placement 
of a stent, a small wired mesh tube, which helps keep the artery open [11].  
There are more invasive procedures, including coronary bypass grafting, commonly 
referred to as bypass surgery. The aim is to divert the flow of blood around an artery that may be 
partially or completely blocked to improve blood flow to the cardiac tissue. For this procedure, a 
healthy blood vessel is taken from the patient’s body, generally from the leg or arm. One end is 
connected to the coronary artery in the heart while the other is connected to the area where there 
is impaired blood flow so that oxygenated blood is able to bypass the blocked area [12,13].  
In cases of severe MI, where normal pacing in the heart is altered leading to arrhythmia, 
the implantation of a pacemaker or implantable cardiac defibrillator, ICD, is necessary [14]. 
ICDs are small, battery powered devices that are implanted just under the skin. Leads from the 
subcutaneous device are inserted tranvenously and advanced into the cardiac tissue. ICDs 
operate by analyzing the electrical activity in the heart and deliver electrical shocks to restore 
normal rhythm if abnormal activity is detected [15]. 
 
C. Arrhythmia 
A healthy heart’s contraction cadence is essential for the efficient circulation of blood 
throughout the body.  The heart has four chambers, the top two are called the atria, and the 
bottom two are called the ventricles. The atria, when relaxed, receive blood from the body and 
contract to move blood to the ventricles. After filling, the ventricles will then contract and push 
the blood to the body.  
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Contractions of the different chambers of the heart are controlled by the propagation of 
electrical signals called action potentials. The action potential wavefront in normal sinus rhythm 
propagates from the SA node, through the atria to the AV node, finally moving through the 
bundle branches and Purkinje fibers into the ventricles allowing for efficient contraction timing 
of the chambers in the heart and for effective blood flow. A cardiac arrhythmia is an irregularity 
with the rate or rhythm of the heartbeat. This abnormality can cause the heart to beat too slow, 
too fast, or with an irregular rhythm [16]. The electrical signals that would normally propagate 
through the cardiac tissue in a coordinated, timely manner now move chaotically through the 
tissue, causing irregular electrical activity in areas, and ill-timed contraction of the of the cardiac 
muscle. Spiral waves, rotors, or re-entrant circuits have become widely accepted as origins for 
many cardiac arrhythmias [17]-[20]. Connections between particular regions of the tissue may 
lead to the “current sink” or “current source” manifestation. Current sinks/sources occur when 
the excitability of a tissue region delivering the depolarization of the current, the source, is not 
equal to the excitability of the tissue region receiving the current, the sink [21] (Fig. 1). These 
electrical waves continually stimulate the tissue at a higher rate than normal sinus rate, inhibiting 
normal conduction in the tissue that can lead to arrhythmia [22].  Although slow conduction 
velocity (CV) may not be the only contributor to reentry in an infarcted area of the tissue, it does 





Fig. 1. This illustration from a fibrillation review by Schotten et al. [20] illustrates the direction 
of propagation for areas of cardiac tissue with varying conduction velocity (CV) speeds. It is 
important to understand that the electrical propagation of the heart depends on the balance 
between the “source” and  “sink” of the depolarizing current. In a convex wavefront, leading 
cells activate more cells in front of it resulting in a small current source, a lower CV, and a 
greater potential for a reentrant circuit to occur. In concave wavefronts, many cells contribute to 
the activation of fewer downstream cells increasing CV [20]. 
 
 
D. Conduction Velocity 
Action potential conduction is a product of complex interactions between cellular 
electrical activity, cardiac tissue structure, and electrical communication between cells. The CV 
of an action potential is vital in the ability for the heart to control the timing of contractions of 
the different chambers. The source-sink relationship, which represents the interactions between 
membrane elements (source) and tissue structure elements (sink), is important to consider when 
discussing CV and its significance in arrhythmia. Slowed CV in particular regions of the cardiac 
tissue is a marker of an underlying issue. There are multiple mechanisms associated with 
conduction slowing. These mechanisms include ischemia, scar tissue formation, cell shape, cell 
size, gap junction expression, and gap junction distribution [23]. These physical properties all 
have the ability to introduce an arrhythmia, making CV an important marker to determine 




E. Engineered Heart Tissue 
Despite advances in both pharmacological and surgical treatments the number of patients 
with MI related deaths have not declined [24]. A marked reduction in quality of life and a high 
mortality rate due to heart failure in patients in not only the US but globally has stimulated the 
need for additional treatment strategies [25]. Engineered heart tissue, EHT, could offer an 
innovative approach to treating areas of infarcted cardiac tissue. 
Scientists have developed patches of myocyte-seeded scaffolds that might be utilized to 
replace diseased areas of a living heart [26]. An EHT should integrate and function with the 
native heart both mechanically and electrically. The complete EHT will be contractile, 
mechanically durable/flexible, able to vascularize quickly upon implantation, and assimilate 
electrically into local cardiac tissue. Unfortunately, an EHT that encompasses all of these ideal 
characteristics has not yet been developed [27]. In essence, the cardiac tissue-engineering field is 
attempting to be able to replace diseased myocardium with prefabricated EHT. Multiple groups 
have been able to construct 3D EHT from neonatal rat heart cells in vitro [25]. The immediate 
issue that must be addressed is the functional properties of the EHT (mechanical function, 
vascular adaptation, electrical function, etc.) and if the EHT is a viable long term solution for 
diseased cardiac tissue. The result of the EHT’s integration should result in improved cardiac 
function without inducing a higher risk for complications. The optimal EHT should have the 
ability to assimilate with the surrounding healthy tissue and maintain all essential cardiac tissue 
function [26]. 
The primary concerns are the ability of the EHT patches to improve function of the 
damaged cardiac tissue area and not serves as a catalyst for an arrhythmogenic site.  If the EHT 
patch were conducting the action potentials slower than that of the surrounding healthy tissue, 
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then there would be an increased risk for developing an arrhythmia. Therefore, a valuable 
electrical characteristic to establish in the EHT is conduction velocity. 
 
F. Current cardiac tissue characterization techniques 
Cardiac mapping is a general term that includes different types of mapping techniques. 
These various techniques can include electrode arrays or sophisticated optical mapping 
techniques using voltage-sensitive dye and imaging systems with high temporal and spatial 
resolutions [28]. Electrophysiological studies of cardiac tissue often use isolated ex vivo 
characterization techniques that allow for controlled environments without the potential bodily 
interference that may compensate for certain situations in in vitro models; like the nervous 
system increasing heart rate via epinephrine [29].  
Extracellular electrograms are considered the hallmark of invasive cardiac 
electrophysiology and provide essential information about the electrical activity in the 
underlying myocardium. An extracellular electrogram may be recorded from an electrode array 
in direct contact with cardiac tissue. The electrograms are created by the depolarization of the 
cardiomyocytes that generate transmembrane currents in the extracellular space. Under 
pathological conditions, however, electrograms may consist of unusual components that are 
attributed to abnormal CV [30]. In the case of in vitro analysis, a system to maintain 
physiologically relevant environment where pH and temperature are controlled is needed. 
Dulbecco’s Modified Eagle Medium (DMEM, balanced salt solution) mixed with CO2 has been 
previously used in order to provide a suitable environment as well as tissue viability [29, 31]. 
This bath system can also be used in-vivo and may be used to characterize pieces of cardiac 
tissue as well as EHT. 
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A successful ex vivo cardiac mapping experiment hinges upon two primary targets: 
1. Tissue viability must be maintained in order to give relevant data. Perfusion technique, 
nutritional medium, O2-CO2 interaction to maintain pH balance, and temperature control 
can be used to ensure normal tissue function. 
2. Comparative analysis of current and past electrical conduction in tissue sample results to 
determine effectiveness of environment control. 
Previous work at University of Memphis has produced an inexpensive and simple tissue 
bath system to maintain a physiologically relevant environment for isolated ex vivo cardiac 
tissues [29], a data acquisition system to record extracellular electrograms, and data analysis 
software to determine activation time of the tissue [32]. Activation time data was then 
processed offline to give CV characteristics of the tissue [29].   
 
G. Objectives 
The overall objective of this study is to develop a cardiac mapping system to reliably 
determine activation time sequences in cardiac tissue samples. From these calculations, we 
determine CV for the tissue sample and translate that information into conduction characteristics 









Project objectives include: 
1. Construct an inexpensive and simple electrode array that can be used to interact 
with cardiac tissue samples.  
2. Develop a data acquisition and analysis system that can be used to determine 
activation times of the tissue, calculate CV, and identify and flag areas of the 
tissue that display abnormal conduction tendencies. 
3. Perform experiments using porcine cardiac samples to evaluate the performance 
of our system on the response of the tissue to current stimuli. 
4. Expand and update the previous methods in the lab of cardiac tissue 
characterization. 
The method of cardiac tissue analysis via electrode mapping array along with an analysis 
program to determine regions of abnormal conduction in semi-automated will serve as a valuable 
tool to identify arrhythmic prone regions within the tissue sample. This method may have the 






The methods followed in this project were from a recognized standard from researchers 
and scientists in cardiac mapping [31]. These practices include determining stimulation/response 
threshold values, activation time calculations, as well as CV characteristics. Initial methods 
directly follow work previously performed in the lab by Villa [29]. 
 
A. Tissue bath development 
A rectangular acrylic chamber used in previous studies was used as the tissue bath system 
chamber. Tissue clamps anchored to the bottom of the chamber hold the tissue samples in place 
during stimulation and recording. Physiological temperature was maintained by setting the 
chamber in a water bath continually heated via a ceramic hotplate. The chamber was filled with 
DMEM (Lonza BioWhittaker™ Dulbecco's Modified Eagle's Medium from Fisher Scientific) to 
a level that completely submerged the tissue by 1-2 mm [29,31]. The DMEM was continuously 
circulated at 120 ml/min using a Masterflex tubing pump. Temperature was controlled inside the 
chamber at 37±0.5 °C by using the hotplate with controller (IKA® C-MAG HP7 and 
IKATRON® ETS-D5, respectively); water level inside the metal pan was filled to surpass the 
level of the medium within the chamber. Water must be monitored and added throughout the trial 
as evaporation occurs during the experiment. The pH was maintained between 7.32±0.04 by 






Fig. 2. Cross-sectional view of the constructed tissue bath system to maintain appropriate 
physiological conditions for cardiac tissue samples [29].  
 
B. Tissue sample preparation 
Our system’s ability to maintain appropriate physiological conditions was tested using 
porcine cardiac tissue. Porcine samples were acquired from Dr. Randal Buddington, Professor, 
School of Health Studies, University of Memphis.  Piglet age varied from 5 weeks to 13 weeks. 
Piglets were euthanized using a cardiac and respiratory knockout, SomnaSol Euthanasia solution.  
The freshly removed heart was immediately placed on ice and transported, in under ten 
minutes, to the lab for analysis. The heart was rinsed in warmed saline to help prevent potential 
blood clot formation that may interfere with electrical stimuli and data recording. Dissection 
involved removing both atria as well as the right ventricle. The left ventricle was cut through the 
interventricular wall to allow the tissue to lay flat with the epicardium of the left ventricle facing 
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upward and paced into the tissue bath system, completely submerged by the DMEM solution, 
secured by the tissue clamps, and allowed to settle for 5-7 minutes to stabilize. During this time, 
the tissue was continuously evaluated for viability; this assessment was based on color, texture, 
and firmness of the tissue. Experiment was ended when the tissue became hard or if no electrical 
response was observed following stimulation.  
 
C. Electrical characterization of the cardiac tissue 
Mapping system: The mapping system we developed consists of an array of 11x11 
Ag/AgCl coated copper electrodes (Fig. 3 A), and a reference electrode (Fig. 3 B) connected to a 
data acquisition system with LabVIEW interface. Each tissue sample was stimulated, via current 
stimulation program developed in LabVIEW and driven through a current Output Module 
designed for CompacDAQ (NI 9265; 4-Channel, 0 mA to 20 mA, 16-Bit Analog Output Module; 
National Instruments, Austin, TX.). The system contains 3 modules (NI 9205; 32-Channel, ±200 
mV to ±10 V, 16-Bit Analog Input Module; National Instruments, Austin, TX.) that use 27 
channels for amplification and filtration each which produce 81 total electrical channels for data 
acquisition. Electrograms, in the form of analog signals, recorded from each of the electrodes 
within the 9x9-recording matrix are transferred individually through a Compact DAQ (NI-cDAQ 
9174; 16-Bit Analog NI CompactDAQ; National Instruments, Austin, TX.) to a Dell Optiplex 
GX620 computer where data is collected and displayed as individual electrograms. These 
electrograms are then processed through a programmed LabVIEW interface where two-




A.   B.  
 
Fig. 3. (A) Electrode array: 9x9 recording electrode matrix, 0.254 mm electrode diameter, 0.61 
mm separation between electrodes. (B) Reference electrode (28 mm x 34 mm) was constructed 
from silver foil and electroplated (Ag/AgCl) [29]. 
 
Stimulation and mapping protocol: The protocol for stimulation and mapping followed 
previous efforts in the lab by Villa [29]. The pacing threshold was found by delivering a square 
wave stimulus, 3 ms pulse width, at 1 Hz for 5 s, from a line of electrodes that borders one side 
of the electrode array. The initial amplitude for the stimulus started at 0.5 mA and was increased 
by 0.1 mA until tissue activation was achieved (Fig. 4 and Fig. 5). Once a pacing threshold was 
verified, the tissue samples were stimulated at 1.5 times the pacing threshold value and 
electrograms were recorded for episodes of 20 s. After successful tissue activation and recording, 
temperature and pH levels were recorded to continually maintain applicable physiological 
conditions.  
Fig. 4 A-C were obtained from previous experiments [29] where tissue activation was 
achieved following current input. Due to the limited porcine samples tissue activation was not 
achieved in our experiments. Fig. 5 shows results from our efforts in the lab. Although tissue 
activation was not achieved the experiment, we successfully mapped electrical potential changes 
in all 81 of our mapping electrodes as well as successfully developed a current stimulation 















Fig. 4. (A) Electrogram recording from a porcine tissue sample at an electrode 8 mm (vertical 
distance) from the stimulation site from which a 0.7 mA stimulus was delivered. The large 
negative deflection is the stimulus artifact. (B) An active response was achieved after the 
stimulus artifact at the same electrode location as Fig. 3. The stimulus delivered was 0.9 mA, the 
activation threshold for this tissue sample. (C) The first derivative of the signal in (B) is shown. 
The first large negative/positive deflection corresponds to the stimulus artifact. The nadir of the 

































Fig. 5. (A) View of the user interface for all 81 mapping electrodes for the current LabVIEW 
program. The stimulus artifact is seen in all 81 of the mapping electrodes. There is no large 
deflection detected following the stimulation suggesting tissue activation was not achieved. 
Single (B) electrode view from (A). The LabVIEW program allows the user to individually 
monitor a single electrode. Again, the stimulus artifact is seen in the single electrode. There is a 
small deflection following the stimulus artifact. However, the amplitude as well as the duration 







D. Data Analysis 
Electrograms for each of the individual electrodes were evaluated to determine if the 
underlying tissue was activated. The activation time for each electrode was found as the 
maximum negative value of the first derivative (dV/dt) from its respective electrogram during 
the pacing cycle (Fig. 4) [33]. An electrode was considered active if the maximum negative value 
was less than -0.5 V/s [34]. Pacing episodes data was analyzed for electrical wavefronts, and 
episodes that displayed an electrical wavefront across entire electrode array were selected for 
data analysis. These data sets were evaluated using a LabVIEW VI (Virtual Instrument) 
developed to analyze the electrode matrix data. The programed LabVIEW VI reviews the spatial 
distributions of activation times. If the activation time difference of a given electrode was greater 
than two standard deviations compared to the window of 3 to 6 surrounding electrodes, the value 
was considered an outlier and the value is eliminated. A MATLAB script was developed to 
import data from the LabVIEW VI that also displays relative activation times of each individual 
electrode as a contour plot, calculates conduction velocity speed and direction, and identify areas 
of the tissue that exhibit slow CV speeds that are considered arrhythmic prone.  
Conduction velocity describes the local magnitude and direction of electrical propagation 
activity in the heart tissue and may fluctuate depending on tissue properties, fiber orientation, 
gap junction placement, and previous activity, all of which have the ability to change over time 
and significantly differ depending on location within the tissue [35].  The magnitude of 
conduction velocity was measured by determining the direction of propagation and calculating 
the distance a particular wave front travels over the difference in time of activation between two 
electrode points. After tissue activation times were determined for the individual electrodes, CV 
vectors representing the speed and direction of electrical propagation were calculated using a 
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MATLAB script. This MATLAB script uses previous methods provided by Bayly et al. [36]. The 
method uses spatial windows that are defined as six or more adjacent electrodes that have 
recorded activation times. The spatial windows are then projected as velocity vectors from the 
partial derivatives of fitted polynomials T(x,y) to a data set of spatial activation points (x,y,t) 
using a least squares fitting procedure, where x and y are locational characteristics of the 
electrodes within the electrode matrix and t is the time the particular electrode was activated 
based on the criteria previously mentioned. An activation time contour plot and CV vector plot is 
displayed to allow for a quick analysis of the overall electrical propagation. The conduction 
velocity is then plotted into an intensity graph where speeds are represented as normal 
conduction speed (green), or slow conduction speed/arrhythmic prone site (red). Abnormal CV 
speed that is flagged using red is under 0.08 m/s. Areas that display CV speeds slower that 0.08 
m/s are highly susceptible to reentrant circuits, a major cause of arrhythmia [40]. This allows for 
real time analysis and determines if/where an arrhythmic prone site is located within the 
electrode array portion of the cardiac tissue. The mean conduction speed for each pacing episode 





This research investigates the capability of cardiac mapping system in two manners. First, 
the electrode array must be validated; the electrode array must drive a desired current through a 
line of electrodes as well as determine electric potential changes in individual electrodes to map 
electrical propagation on the surface of the tissue substrate. Second is the ability to determine 
activation times in each of the 81 mapping electrodes, calculate conduction velocities, and 
identify areas within the 9x9 mapping region that present arrhythmic prone CV speeds. 
Preliminary testing in saline solution procedure and results are shown in Appendix D. 
 
A. Activation Thresholds 
Activation thresholds are defined as the minimum stimulus amplitude required achieving 
a response from the tissue sample. The VI built in LabVIEW allows the user to manipulate both 
the amplitude, pulse width, duration of stimulus, and pulse interval of the current to create the 
desired current waveform. Amplitude for current in all five porcine experiments began with a 
current of 0.65 mA and a pulse width of 3 ms and was increased by 0.1 mA until 1.4 mA 
amplitude was reached. Activation thresholds for previous experiments performed by Villa [29] 
were found at 0.88±0.09 mA; however, due to the limited number of porcine samples available 
activation thresholds were not achieved. 
 
B. Activation Time Identification and Conduction Velocity Analysis 
Activation times for individual electrodes are necessary in determining both electrical 
wavefronts and conduction velocity. Previously, relative activation times were determined 
through extensive post processing by the user. Now, the LabVIEW VI that has been developed is 
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able to determine relative activation times of individual electrodes immediately following a 
pacing episode. This is achieved by a windowing mechanism that allows the investigator to 
select epochs of raw data to be analyzed and processed. Once a particular set of data is found and 
processed it is converted into a set of data for each electrode (X electrode position, Y Electrode 
position, Activation time). These values are then recorded and manually exported as an Excel 
spreadsheet. Next, the Excel spreadsheet is imported into a MATLAB program that displays 
activation time contour plots. Because tissue activation was not achieved in porcine experiments 
previous data from the Villa experiments were used to verify activation time determination 
method. The activation times are plotted as a function of space (mm) of the 9x9 electrode 
recording region. Fig. 6 shows a contour map for activation times for two sets of former porcine 
data. The activation contour maps show the distribution of activation times at regions of the 
cardiac tissue. We expected and observed increased activation times as the electrical wavefront 
propagated from the line of stimulation electrodes at the bottom of the display.  
Conduction velocity vectors, as previously mentioned, are computed using the developed 
MATLAB program employing the method described by Bayly et al. [36]. Qualitative inspection 
of the velocity vector field shows an overall direction of flow from the line of stimulating 





A)  B)  
Fig 6. (A) Contour plot of activation times (ms) of the 9x9 mapping portion of the electrode 
array. Stimulation occurred from the bottom of the electrode array. As expected the activation 
times increase as the wavefront propagates away from the line of stimulation electrodes at the 
bottom edge of the array. The contour plot is shown as an 8x8 square due to the polynomial 
fitting window used to interpolate activation times between electrodes. B) Velocity vector field 
plot of (A) activation time data. The electrical propagation is moving away from the stimulation 
row of electrodes. 
 
 
C. Arrhythmic Prone Site Detection 
As seen in Fig. 7 (A and B) there are no regions within the 9x9 mapping electrodes for 
the two porcine samples that display CV speeds that are considered abnormal. To verify the 
identification method of abnormal CV sites, activation times for a particular region within the 
9x9 window were manually altered to slow the CV. Fig. 8 demonstrations a complete user 
interface display of activation time contour plot, CV vector field, CV contour plot, as well as the 




A)  B)  
Fig. 7. (A) Contour plot of calculated CV in m/s from Fig. 6 activation times sample data. 
(B) Arrhythmic prone site identification plot. From the calculated CV speeds in Fig. 7 A. there 
are no abnormally slow CV speeds detected in the data, and green, indicating normal CV, 






Fig. 8. Complete MATLAB interface after data is processed. This particular set of activation time 
data has been manipulated to slow CV speeds in the upper left hand portion of the 9x9 array. 
There are no vectors that appear in the upper left portion of the CV vector field due to their small 
magnitude. This was done in order to verify ability of the program to calculate and identify CV 
speeds of less than 0.08 m/s as “Arrhythmic Prone”. The red area that is identified in the 
“Arrhythmic Prone” site identification panel is displayed by a mechanism created in MATLAB 
that displays any CV speeds less than 0.08 m/s as red. Any CV calculated above 0.08 m/s is 






Fig. 9. Complete MATLAB interface of data that possesses two major arrhythmic prone sites 
based on CV speeds less than 0.08 m/s. Individual electrode activation times were manipulated 
in this data set to contain two areas that display abnormal CVs. There is consistency between all 





 We have been able to design an inexpensive electrode array that has the ability to study 
the electrophysiological characteristics of isolated heart tissue. Due to recent efforts in the 
development of engineered heart tissue patches as a potential treatment for myocardial infarction 
repair, there is a need for a reliable way of determining the electrical properties of isolated 
patches of cardiac tissue.  
We have been able to develop an electrode array complete with a data acquisition and 
analysis program that is able to detect changes in electrical potential for individual electrodes. 
Mechanisms within the analysis program have the abilities to send a desired current input 
through selected electrodes, record the electric potential changes in the cardiac tissue sample, 
and assign the appropriate activation time to the individual mapping electrodes. These activation 
times are then translated into conduction velocities over the mapping portion of the electrode 
array. Finally, the program is able to identify areas within the mapping window that displays CVs 
that would allow a reentrant circuit to develop. 
The system was verified using porcine tissue samples that were placed in a controlled 
tissue bath system that maintained normal physiological conditions.  The system has the ability 
to control temperature, pH, and the circulation of the medium using a feedback control system.  
The protocol for determining activation threshold is common among literature in cardiac 
mapping. Tissue is stimulated with an electrical current and is continually increased until an 
active response is achieved in the tissue sample (29, 31, 41). We followed the correct procedure 
for finding activation threshold but were unable to achieve tissue activation in the porcine 
samples. We believe this is due to the limited porcine tissue trials. We were able to verify that 
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that current stimulation portion of the LabVIEW allows the user the ability to change current 
amplitude, pulse width, and frequency. 
Conduction velocity is calculated using the same method performed by Bayly et al. [36] 
and described in Methods section (II.D). This provides real-time visual feedback on the 
magnitude and speed of electrical propagation, and is used to indicate potential arrhythmic prone 
regions. There are other methods that only measure the magnitude of CV across the tissue. The 
visualization of the vector field enhances the ability of our system to also show the direction of 
electrical propagation. Future work would allow the direction of vector fields to also play a part 
in the identification of an arrhythmic prone site.  
26 
 
V. Recommendations, Limitations, Future work 
One of our objectives was to expand and update previous efforts within the lab for 
electrical characterization of isolated cardiac tissue. We believe we have not only fulfilled this 
objective but have opened up more avenues for future research, in our lab, to explore. 
 
A. Recommendations 
The ability to maintain tissue sample stability within the tissue bath was not as effective 
over a large range of tissue sample sizes. The porcine samples that we received varied greatly in 
size due to variation in animal ages. This made securing the larger isolated samples difficult 
using the current clamps in the tissue bath. We therefore recommend searching for an alternative 
clamping mechanism that that easily adjusts for varying sizes of samples due to the wide age 
range of samples we receive in the lab. 
A bath tissue system upgrade is recommended, as the viability of the cardiac tissue is 
essential in achieving accurate recordings. The tissue bath offers a great deal of control as far as 
maintaining relevant physiological conditions is concerned. This is accomplished by having 
multiple tubes, electrodes, meters, and wires being placed into the tissue bath. This causes an 
issue when trying to maneuver the electrode array to various regions of the tissue where multiple 
controlling components need to be held into the DMEMs solution. We suggest updating the 
acrylic chamber with permanent clamps to secure the various controller components in the tissue 
bath to enable more room for the experimenter to operate. 
Currently, the “arrhythmic prone” identification mechanism is only taking CV magnitude 
into consideration for identifying areas that display abnormal CV. Based on literature a CV speed 
less that 0.08 m/s is considered abnormal. This is not the only property that can cause a reentrant 
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circuit. A mechanism that also characterizes the angle differences in sequential CV vectors may 




As previously mentioned, the number of porcine samples available to study limited our 
ability to be successful in observing tissue activation in our porcine sample studies. Because of 
this limitation we were unable to verify the cardiac tissue mapping electrode array to determine 
pro-arrhythmic tissue substrates using a single porcine sample. Nonetheless, we verified the 
electrode array by importing previously recorded data and simulating different conduction 
scenarios. Further studies in porcine or small animals tissues such as rat or guinea pig should be 
performed. 
The number of mapping electrodes is limited by the number of available slots in the 
individual modules that are compatible with MATLAB. The 9x9-mapping surface is smaller than 
previous work done in the lab that used an 11x11-mapping surface. There are 144 available slots 
for electrodes in the current DAQ system. If the mapping surface is needed to be larger than 
12x12 alternative methods must be used. 
Finally, another significant limitation was the rigidity of the electrode array itself. We are 
trying to map using a flat surfaced electrode array on a curved surface of cardiac tissue. Slight 
pressure is necessary to maintain sufficient contact for all electrodes in the array. The design of a 





C. Future Work 
This study has provided a significant upgrade within the lab for the mapping system for 
electrical properties in isolated cardiac tissue. The device that has been developed is intended for 
further cardiac mapping efforts within the lab as well as in the development and research of 
engineered cardiac tissue patches. These patches have been characterized mechanically [43]; the 
next progression before in-vivo animal models is to characterize the patches electrically. 
The recent upgrades to the mapping system as well as previous efforts in the lab that have 
provided adequate baseline electrophysiological activity for both porcine and rats that will allow 































 Advances in our understanding in both biomaterials and cellular scaffolds have opened 
up many novel approaches in resolving medical diseases we have today. Ex vivo characterization 
of these prospective approaches serve as a valuable platform for predicting the scaffold potential 
viability as a solution to manage myocardial infarction. 
 The system we have developed offers a portable and accessible option for ex-vivo 
electrical characterization of isolated cardiac tissue. The primary limitation in ex-vivo 
characterization of cardiac tissue is the time to analyze a particular recording; the programming 
allows for real time analysis instead of extensive offline efforts. This system has the ability to 
analyze the activation times of 81 mapping electrodes, calculate CV vector fields, display CV 
contour plots, and identify areas within the mapping window that display CV speeds that are 
considered “arrhythmic prone”. This system coupled with a formerly developed tissue bath 
system [29] allows for characterization of cardiac tissue from both rats and piglets in 
physiologically relevant conditions. 
 Results from this study will provide a foundation for future research in which arrhythmic 
prone sites are characterized and identified on isolated cardiac tissue/ engineered cardiac patches. 
The ex-vivo recognition of arrhythmic prone sites will serve as a valuable tool when determining 
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A. List of abbreviations 
CHD: coronary heart disease 
ICD: Implantable cardioverter-defibrillator  
EHT: Engineered heart tissue 
CV: conduction velocity 
ECG: electrocardiogram  
MI: myocardial infarction  
DMEM: Dulbecco's Modified Eagle's Medium 




B. Protocol for isolated porcine heart tissue mapping. 
 
Date: ____________________ Weight (grams): ___________ Piglet number: ______________ 
Time of death: _____________  
 
1) Prepare medium and saline in warm bath (room 316) and wait for them to reach 37°C.  
2) Prepare bath close to mapping system with warm water, and connect necessary cables.  
3) Pick up heart from Dr. Buddington, psychology building. Place in ice and transport to 
Engineering Technology Building.  
4) Prepare bath with warmed DMEM, place temperature controller and turn on Hot plate and pH 
Controller.  
5) Rinse in warmed saline. Section LV tissue. Place in bath. Time: __________, 
pH:____________, Temperature: ____________  
6) After 5-10 min. Rare spontaneous beating, determine threshold value. Run 5 seconds pacing at 
1 beat per second, Recording last 4s, start at 0.5 mA amplitude and increase by 0.1mA until 
active response achieved.  
Time:__________,Threshold value: _____________  
7)  Run two 5 seconds pacing episodes  
 Filenames: _____________ _______________   
pH:__________, Temperature____________   
8)  Run two 10 seconds pacing episodes  
Filenames: _____________ _______________  
 pH:__________, Temperature____________   
9)  Run two 20 seconds pacing episodes  
Filenames: _____________ _______________  
 pH:__________, Temperature____________   
10)  Run two 60 seconds pacing episodes  
 Filenames: _____________ _______________   
pH:__________, Temperature____________   
11)  Run two 300 seconds pacing episodes  
 Filenames: _____________ _______________  




C. MATLAB program developed to obtain conduction velocity.  
 
%Matlab code to obtain the conduction velocity vector fields and mean 
%conduction velocities% 
%Thomas Shannon Fall 2015-Spring 2016 
clear all 
  













%The following Polynomial fitting work completed by Emanuel Villa and 
%edited by Thomas Shannon 
% create variable to calculate the length of the data LOD=length(data)% 
LOD=length(data); 
for i=1:LOD, 
        V=data(i,:); 
    count=0;clear window; clear window2; 
    for j=1:LOD, 
        if(abs(data(j,1)-V(1))<3 && abs (data(j,2)-V (2))<3 && abs(data(j,3)-V (3))<4) 
            count=count+1; 
            window(count,:)=data(j,:); 
        end 
    end 
    if length(window)>8 
        variance(i,1)=var(window(:,3)); 
        av_keep=(window(:,3)>0); 
        Sums=sum(window(:,3).*av_keep); 
        countav=sum(av_keep); 
        average(i,1)=Sums./countav; 
        count2=0; 
        for k=1:length(window(:,1)) 
            if window(k,3)>(0.3*average(i)) && window (k,3)<(1.7*average(i)) 
                count2=count2+1; 
                window2(count2,:)=window(k,:); 
                %remake the array from window data% 
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                if exist('CT','var') 
                    CT=[CT;window2(count2,:)]; 
                else  
                    CT(1,:)=window2(1,:); 
                end 
            end 
        end 
        modelterms=[2 0;0 2;1 1;1 0;0 1;0 0]; 
        polymodel2=polyfitn(window2(:,1:2),window2(:,3),modelterms); 
        %polyfitn function downloaded from internet% 
        a=polymodel2.Coefficients(1); 
        b=polymodel2.Coefficients(2); 
        c=polymodel2.Coefficients(3); 
        d=polymodel2.Coefficients(4); 
        e=polymodel2.Coefficients(5); 
        f=polymodel2.Coefficients(6); 
        x=data(i,1); 
        y=data(i,2); 
        Tx=2*a*x+c*y+d; 
        Ty=2*b*y+c*x+e; 
        Vx(i,1)=Tx/(Tx*Tx+Ty*Ty); 
        Vy(i,1)=Ty/(Tx*Tx+Ty*Ty); 
        vel(i,:)=[x,y,Vx(i),Vy(i)]; 
        mag(i,1)=sqrt(((Vx(i))^2)+((Vy(i))^2)); 
        R2(i,1)=polymodel2.R2; 
        RMSE(i,1)=polymodel2.RMSE;         
        NRMSE(i,1)=polymodel2.RMSE/(maxt-mint); 
        Z(i,1)=a*data(i,1).^2+b*data(i,2).^2+c*data(i,1).*data(i,2)+d*data(i,1)+e.*data(i,2)+f; 
        resid(i,1)=abs(Z(i,1)-data(i,3)); 
        if (R2(i)<0||abs(mag(i))>3||resid(i)>1||isnan(resid(i))) 
            velcorr(i,:)=[0,0,0,0]; 
            mag(i,1)=0; 
            resid(i,1)=0; 
            R2(i,1)=0; 
        else 
            velcorr(i,:)=vel(i,:); 
            mag(i,1)=sqrt(((Vx(i))^2)+((Vy(i))^2)); 
            resid(i,1)=abs(Z(i,1)-data(i,3)); 
            R2(i,1)=polymodel2.R2; 
        end 
    end 
    count=0; 
end 
  





%Activation Time contour 
AT=subplot(2,2,1) 
xv = linspace(1, 9, 50); 
yv = linspace(1, 9, 50);  
[Xinterp,Yinterp] = meshgrid(xv,yv); 
Zinterp = griddata(contourx,contoury,contourz,Xinterp,Yinterp);  
contourf(Xinterp,Yinterp,Zinterp); 
[c,h]=contourf(Xinterp,Yinterp,Zinterp, 10); clabel(c,h);    





title('Contour Plot of Activation times (ms)') 
xlabel('X axis (0.635 mm spacing between electrodes)') 
ylabel('Y axis') 
  







title('Conduction Velocity Vectors') 









AP=sqrt(AVX.^(2)+AVY.^(2));                  %ABSOLUTE VELOCITY OF VECTORS 
         
xx = linspace(1, 9, 50); 
yy = linspace(1, 9, 50);  
[Xinterp,Yinterp] = meshgrid(xx,yy); 
AZinterp = griddata(X,Y,AP,Xinterp,Yinterp); 
contourf(Xinterp,Yinterp,AZinterp); 
[C,h]=contourf(Xinterp,Yinterp,AZinterp, 10); % Adds contour level labels on 
v=[0.08]; 




              % CV identified at 0.08 M/sec as Arryhthmic prone. 
                 %Forces a contour if any CV values are found at 0.08 M/sec 





xlabel('X axis (0.635 mm spacing between electrodes)') 
ylabel('Y axis') 





contourf(Xinterp,Yinterp,AZinterp, [min(AZinterp(:)); .08]); 
colormap([1,0,0; 0,1,0])                                  
                                                            
                                               
                                                   




xlabel('X axis (0.635 mm spacing between electrodes)') 
ylabel('Y axis') 





D. Preliminary data using saline solution. 
 
 
Prior to porcine experiments, bench tests were performed in saline solution to verify 
current stimulation waveform through the peripheral row of electrodes as well as confirm 
individual electrode recordings. For this experiment, the electrode array was suspended freely in 
a beaker of saline solution. The following results verify we were able to deliver current through 
the stimulation row of electrodes as well as record the voltage potential in the 81 mapping 
electrodes seen in Fig. 10. In Fig. 11 we have our initial, or bench test, peak detector configured 
to determine the stimulus artifact in saline solution. In porcine experiments, we changed the peak 
detector criteria to determine tissue activation rather than stimulus artifact.  
 
 
Fig. 10. Preliminary LABVIEW display showing voltage response to a single square wave 
current pulse in saline solution for 81 mapping electrodes. The large deflection seen is the 





Fig. 11. Peak times of 81 mapping electrode recordings in saline solution experiments. The table 
represents the spatial location of the 9x9 array of electrodes. The peak detector was configured to 
detect stimulus artifact and 70 out of the 81 recordings show peak time of 804-808 ms. This is 
consistent with the time of the leading edge of the stimulus waveform in 70 recordings 
